| inj | injection; injury, injured, injurious |
|---|---|
| DIG | digitalis; digoxin; drug-induced galactorrhea |
| dig | digitalis; digoxin |
| DLIS | digoxin-like immunoreactive substance |
| DLTS | digoxin-like immunoreactive substance |
| DLIF | Digoxin like immunoreactive factor |
|---|---|
| DLIS | Digoxin-like immunoreactive substance |
| SDC | Serum digoxin concentration |
| digoxin | <chemical> A cardiotonic glycoside obtained mainly from digitalis lanata; it consists of three sugars and the aglycone digoxigenin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. Pharmacological action: anti-arrhythmia agents, cardiotonic agent, enzyme inhibitors. Chemical name: Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (12 Dec 1998) |
|---|---|
| digoxin toxicity | A result of the over-accumulation of digitalis glycosides in the body. Kidney insufficiency can be a contributing factor. Symptoms include nausea, vomiting, visual changes, blurred vision, anorexia and palpitations. Treatment is emergent as life-threatening cardiac arrhythmias are possible with higher blood levels. (27 Sep 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|